Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.

Frontiers in immunology - 1 Jan 2018

Besson Laurie, Charrier Emily, Karlin Lionel, Allatif Omran, Marçais Antoine, Rouzaire Paul, Belmont Lucie, Attal Michel, Lombard Christine, Salles Gilles, Walzer Thierry, Viel Sébastien

Abstract excerpt

Multiple myeloma (MM) is a proliferation of tumoral plasma B cells that is still incurable. Natural killer (NK) cells can recognize and kill MM cells in vitro and can limit MM growth in vivo. Previous reports have shown that NK cell function is impaired during MM progression and suggested that treatment with immunomodulatory drugs (IMIDs) such as lenalidomide (LEN) could enhance it. However, the effects of IMIDs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody-Dependent Cell Cytotoxicity
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Immunophenotyping

Share to Killer Cells, Natural

Share to Lenalidomide

Share to Lymphocyte Count

Share to Multiple Myeloma

Source

Open in PubMed Open full text

Identifiers

PMID: 29706958
DOI: 10.3389/fimmu.2018.00704
PMCID: PMC5908898

Genes

SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.PMID 29706958Read ↗

Single-cell transcriptomic analysis of NK cell dynamics in myeloma patients reveal persistent reduction of cytotoxic NK cells from diagnosis to relapseSemantic proximity Read ↗

Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.Semantic proximity Read ↗

Single-cell profiling of human bone marrow reveals multiple myeloma progression is accompanied by an increase in CD56 <sup>bright</sup> bone marrow resident NK cellsSemantic proximity Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

Integrative Genomic, Single-Cell, and Functional Profiling of the CD48–CD244 Axis and NK-Cell Dysfunction in Multiple MyelomaSemantic proximity Read ↗

Inflamed Natural Killer cells with adhesion defects are associated with a poor prognosis in Multiple MyelomaSemantic proximity Read ↗

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class ISemantic proximity Read ↗

Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myelomaSemantic proximity Read ↗

Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.Semantic proximity Read ↗

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.Semantic proximity Read ↗

Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.Semantic proximity Read ↗

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.